Cardiovascular disease (CVD) remains the major cause of death and disability worldwide, and residual risk after implementing all current therapies is still high. In this context, the latest (2016) European Cardiology Society/European Atherosclerosis Society guidelines recommend that triglyceride (TG)-lowering drugs should be used in high-risk patients with TGs levels >2.3 mmol/L (200 mg/dL), after lifestyle measures fail to lower them. After several neutral CVD outcome trials with n-3 fatty acids, the Reduction of Cardiovascular Events with EPA–Intervention Trial met its primary end point, that is, among patients with elevated TGs levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower in those who received 4 g of icosapent ethyl daily. In this review, we comment on the findings of previous and recently published randomized controlled CVD outcome trials assessing n-3 fatty acids supplementation. Both efficacy and safety, as well as future perspectives, are discussed.
RothGAJohnsonCAbajobirAet al.Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.
2.
NordestgaardBG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–63.
3.
KolovouGDMikhailidisDPKovarJet al.Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9(3):258–70.
4.
CatapanoALGrahamIDe BackerGet al.2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
5.
SiscovickDSBarringerTAFrettsAMet al.Omega-3 polyunsaturated fatty acid (Fish Oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135(15):e867–84.
6.
AungTHalseyJKromhoutDet al.Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3(3):225–34.
7.
Delgado-ListaJPerez-MartinezPLopez-MirandaJPerez-JimenezF. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012;107(Suppl 2):S201–13.
8.
BhattDLStegPGMillerMet al.Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
9.
RoncaglioniMCTombesiMAvanziniFet al; Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800–8.
10.
ORIGIN Trial InvestigatorsBoschJGersteinHCDagenaisGRet al , n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18.
11.
ASCEND Study Collaborative Group, BowmanLMafhamMWallendszusKet al.Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540–50.
12.
MansonJECookNRLeeIMet al.Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32.
13.
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354(9177):447–55.
14.
YokoyamaMOrigasaHMatsuzakiMet al.Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.
15.
NichollsSJLincoffAMBashDet al.Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41(10):1281–8.
16.
EussenSRGeleijnseJMGiltayEJRompelbergCJKlungelOHKromhoutD. Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. Eur Heart J. 2012;33(13):1582–8.
17.
de LorgerilMSalenPDefayePRabaeusM. Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?BMC Med. 2013;11:5.
18.
HeydariBAbdullahSPottalaJVet al.Effect of Omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial. Circulation. 2016;134(5):378–91.
19.
KimCHHanKAYuJet al.Efficacy and safety of adding omega-3 fatty acids in statin-treated patients with residual hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a randomized, double-blind, and placebo-controlled trial. Clin Ther. 2018;40(1):83–94.
20.
WeiMYJacobsonTA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13(6):474–83.
21.
JacobsonTAGlicksteinSBRoweJDSoniPN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6(1):5–18.
22.
DavidsonMH. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013;24(6):467–74.
23.
TheobaldHEChowienczykPJWhittallRHumphriesSESandersTA. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr. 2004;79(4):558–63.
24.
WoodmanRJMoriTABurkeVet al.Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis. 2003;166(1):85–93.
25.
MoriTABaoDQBurkeVPuddeyIBBeilinLJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension. 1999;34(2):253–60.
26.
StarkKDHolubBJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr. 2004;79(5):765–73.
27.
MasonRPDawoudHJacobRFSherrattSCRMalinskiT. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018;103:1231–7.
28.
NelsonJRWaniOMayHTBudoffM. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1–9.
29.
SahebkarASimental-MendíaLEMikhailidisDPet al.Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2018;50(7):565–75.
30.
VerveniotisASiasosGOikonomouEet al.The impact of omega 3 fatty acids in atherosclerosis and arterial stiffness: an overview of their actions. Curr Pharm Des. 2018;24(17):1865–72.
31.
CalderPC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105–15.
32.
KasteleinJJPStroesESG. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380(1):89–90.
33.
NodariSTriggianiMCampiaUDei CasL. Omega-3 polyunsaturated fatty acid supplementation: mechanism and current evidence in atrial fibrillation. J Atr Fibrillation. 2012;5(4):718.
34.
Perez-MartinezPAlcala-DiazJFKabagambeEKet al.Assessment of postprandial triglycerides in clinical practice: validation in a general population and coronary heart disease patients. J Clin Lipidol. 2016;10(5):1163–71.
35.
KolovouGDMikhailidisDPNordestgaardBGBilianouHPanotopoulosG. Definition of postprandial lipaemia. Curr Vasc Pharmacol. 2011;9(3):292–301.
36.
SchirmerSHWernerCMBinderSBet al.Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation. Atherosclerosis. 2012;225(1):166–72.
37.
ChanDCPangJBarrettPHet al , ω-3 fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia. J Clin Endocrinol Metab. 2016;101(10):3732–9.
38.
MiyoshiTNodaYOhnoYet al.Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals—a randomized cross-over trial. Biomed Pharmacother. 2014;68(8):1071–7.
